Free Trial
OTCMKTS:FSNUY

Fresenius SE & Co. KGaA (FSNUY) Stock Price, News & Analysis

Fresenius SE & Co. KGaA logo
$12.49 +0.21 (+1.75%)
As of 03:54 PM Eastern

About Fresenius SE & Co. KGaA Stock (OTCMKTS:FSNUY)

Key Stats

Today's Range
$12.39
$12.62
50-Day Range
$9.96
$12.49
52-Week Range
$7.43
$12.62
Volume
25,394 shs
Average Volume
59,764 shs
Market Capitalization
$27.90 billion
P/E Ratio
65.74
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Buy

Company Overview

Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, dialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment engages in the therapy and care of critically and chronically ill patients. This segment offers I.V. generic drugs; biosimilar drugs for autoimmune diseases and oncology; enteral and parenteral nutrition products; medical technologies, as well as disposables, infusions pumps, apheresis machines, cell therapy devices, and other products. The Fresenius Helios segment provides clinical and nursing care facilities. The Fresenius Vamed segment provides services for hospitals and other healthcare facilities. This segment also offers operational management of healthcare facilities and provides services to patients. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.

Receive FSNUY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fresenius SE & Co. KGaA and its competitors with MarketBeat's FREE daily newsletter.

FSNUY Stock News Headlines

Trump’s treachery
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
Fresenius: Turnaround For Company, Stock Price
See More Headlines

FSNUY Stock Analysis - Frequently Asked Questions

Fresenius SE & Co. KGaA's stock was trading at $8.75 on January 1st, 2025. Since then, FSNUY stock has increased by 42.7% and is now trading at $12.49.
View the best growth stocks for 2025 here
.

Fresenius SE & Co. KGaA (OTCMKTS:FSNUY) announced its earnings results on Wednesday, May, 7th. The company reported $0.23 earnings per share for the quarter, topping the consensus estimate of $0.22 by $0.01. The firm earned $5.92 billion during the quarter, compared to analysts' expectations of $5.41 billion.

Shares of FSNUY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
5/07/2025
Today
5/20/2025
Next Earnings (Estimated)
7/30/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Medical Equipment
Current Symbol
OTCMKTS:FSNUY
CIK
N/A
Fax
N/A
Employees
193,865
Year Founded
1912

Profitability

Trailing P/E Ratio
65.74
Forward P/E Ratio
15.81
P/E Growth
N/A
Net Income
$382.05 million
Pretax Margin
3.84%

Debt

Sales & Book Value

Annual Sales
$24.01 billion
Cash Flow
$1.87 per share
Price / Cash Flow
6.68
Book Value
$9.52 per share
Price / Book
1.31

Miscellaneous

Outstanding Shares
2,234,010,000
Free Float
N/A
Market Cap
$27.90 billion
Optionable
Not Optionable
Beta
0.78

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for May 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (OTCMKTS:FSNUY) was last updated on 5/20/2025 by MarketBeat.com Staff
From Our Partners